1. Han JC, Lawlor DA, Kimm SY. Childhood obesity. Lancet. 2010; 375:1737–48.

2. Elmaoğulları S, Tepe D, Uçaktürk SA, Karaca Kara F, Demirel F. Prevalence of dyslipidemia and associated factors in obese children and adolescents. J Clin Res Pediatr Endocrinol. 2015; 7:228–34.

3. Lobstein T, Baur L, Uauy R; IASO International Obesity TaskForce. Obesity in children and young people: a crisis in public health. Obes Rev. 2004; 5 Suppl 1:4–104.

4. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998; 338:1650–6.

5. McGill HC, McMahan CA, Gidding SS. Are pediatricians responsible for prevention of adult cardiovascular disease? Nat Clin Pract Cardiovasc Med. 2009; 6:10–1.

6. Boullart AC, de Graaf J, Stalenhoef AF. Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta. 2012; 1821:867–75.

7. Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016; 118:138–45.

8. Manco M, Grugni G, Di Pietro M, Balsamo A, Di Candia S, Morino GS, et al. Triglycerides-to-HDL cholesterol ratio as screening tool for impaired glucose tolerance in obese children and adolescents. Acta Diabetol. 2016; 53:493–8.

9. Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M, et al. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care. 2011; 34:1869–74.
10. de Giorgis T, Marcovecchio ML, Di Giovanni I, Giannini C, Chiavaroli V, Chiarelli F, et al. Triglycerides-to-HDL ratio as a new marker of endothelial dysfunction in obese prepubertal children. Eur J Endocrinol. 2013; 170:173–80.

11. Musso C, Graffigna M, Soutelo J, Honfi M, Ledesma L, Miksztowicz V, et al. Cardiometabolic risk factors as apolipoprotein B, triglyceride/HDL-cholesterol ratio and C-reactive protein, in adolescents with and without obesity: cross-sectional study in middle class suburban children. Pediatr Diabetes. 2011; 12(3 Pt 2):229–34.

12. Pacifico L, Bonci E, Andreoli G, Romaggioli S, Di Miscio R, Lombardo CV, et al. Association of serum triglycerideto-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis. 2014; 24:737–43.

13. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr. 2008; 51:1–25.

14. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128 Suppl 5:S213–56.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499–502.

16. Benuck I. Point: The rationale for universal lipid screening and treatment in children. J Clin Lipidol. 2015; 9(5 Suppl):S93–100.

17. Vilela BS, Vasques AC, Cassani RS, Forti AC, Pareja JC, Tambascia MA, et al. The HOMA-Adiponectin (HOMAAD) closely mirrors the HOMA-IR index in the Screening of Insulin Resistance in the Brazilian Metabolic Syndrome Study (BRAMS). PLoS One. 2016; 11:e0158751.

18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–9.

19. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999; 99:2901–7.

20. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet. 2008; 371:117–25.

21. Kavey RE, Mietus-Snyder M. Beyond cholesterol: the atherogenic consequences of combined dyslipidemia. J Pediatr. 2012; 161:977–9.

22. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011; 5:105–13.

23. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002; 43:1363–79.

24. Burns SF, Lee SJ, Arslanian SA. Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth. J Pediatr. 2012; 161:991–6.

25. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123:2292–333.
26. Di Bonito P, Valerio G, Grugni G, Licenziati MR, Maffeis C, Manco M, et al. Comparison of non-HDL-cholesterol versus triglycerides-to-HDL-cholesterol ratio in relation to cardiometabolic risk factors and preclinical organ damage in overweight/obese children: the CARITALY study. Nutr Metab Cardiovasc Dis. 2015; 25:489–94.

27. Lim H, Xue H, Wang Y. Association between obesity and metabolic co-morbidities among children and adolescents in South Korea based on national data. BMC Public Health. 2014; 14:279.

28. Geoffrey R Simon, Cynthia Baker, Graham A Barden 3rd, Brown OW, Hardin A, Lessin HR, et al. 2014 recommendations for pediatric preventive health care. Pediatrics. 2014; 133:568–70.

29. van Wijk JP, Halkes CJ, De Jaegere PP, Plokker HW, Erkelens DW, Cabezas MC. Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis. 2003; 171:109–16.

30. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298:299–308.

31. Nofer JR. Hyperlipidemia and cardiovascular disease: triglycerides - a revival of cardiovascular risk factor? Curr Opin Lipidol. 2011; 22:319–21.